MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY HTN-3, the company’s U.S. clinical trial of renal denervation with the Symplicity® Catheter System™ for the treatment of resistant hypertension (high blood pressure in the presence of three or more medications), an especially dangerous disease affecting hundreds of millions of people worldwide. Patient enrollment in the landmark study is expected to start soon.
